Focus: Catalent is a large-scale Contract Development and Manufacturing Organization (CDMO) headquartered in Somerset, NJ, serving as a critical manufacturing and formulation partner for pharma and biotech companies globally. With 10,001-50,000 employees and public market status, it operates as a backbone infrastructure provider in the pharmaceutical supply chain.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Hot — 356 jobs added in 30d
Net +161 (356 new, 195 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 324 affected
Source: state DOL filings via Big Local News
Catalent offers stable manufacturing and operations roles in a well-established CDMO, but post-acquisition integration risks and organizational restructuring create near-term career uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic ANDA post-loss of exclusivity; represents mature portfolio asset with minimal growth trajectory.
Help build intelligence for Catalent
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Catalent's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Off-patent allergy medication; stable revenue base typical of generic ANDA portfolio.
Established anti-epileptic generic with stable demand; demonstrates Catalent's capacity in specialty generics manufacturing.
Generic antihistamine; stable portfolio asset in the allergy/OTC space.
1 discontinued, 0 duplicate formulations not shown
Cartherics, Catalent Expand Partnership - Contract Pharma
Cartherics, Catalent Expand Partnership Contract Pharma
Novo Nordisk cuts 400 roles at troubled Bloomington site - Fierce Pharma
Novo Nordisk cuts 400 roles at troubled Bloomington site Fierce Pharma
Layoff Tracker: BioNTech will close Singapore plant, affecting 85 employees - BioSpace
Layoff Tracker: BioNTech will close Singapore plant, affecting 85 employees BioSpace
Catalent Inc stock delisted after 2023 Novo Nordisk acquisition faces ongoing integration uncertaint - AD HOC NEWS
Catalent Inc stock delisted after 2023 Novo Nordisk acquisition faces ongoing integration uncertaint AD HOC NEWS
Catalent Inc stock faces uncertainty after 2023 Novo Nordisk acquisition amid evolving pharma servic - AD HOC NEWS
Catalent Inc stock faces uncertainty after 2023 Novo Nordisk acquisition amid evolving pharma servic AD HOC NEWS
New agreement for Unifor Catalent members includes improvements to wages and benefits - unifor.org
New agreement for Unifor Catalent members includes improvements to wages and benefits unifor.org
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent WARN filing and stock delisting indicate ongoing post-acquisition integration turbulence; restructuring risk remains elevated through 2026.
Recent peer-reviewed publications with author affiliations at this company
Leveraging analytical and bioprocess platforms for biological product development and commercialization - A meeting report.
Validated GMP banking of a new set of genomically stable induced pluripotent stem cell lines using single-cell passaging.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo